Assessing intrinsic renal sodium avidity in acute heart failure: implications in predicting and guiding decongestion

Pieter Martens, Horng H Chen, Frederik H Verbrugge, Jeffrey T Testani, Wilfried Mullens, W H Wilson Tang, Pieter Martens, Horng H Chen, Frederik H Verbrugge, Jeffrey T Testani, Wilfried Mullens, W H Wilson Tang

Abstract

Aim: Intrinsic renal sodium avidity (IRSA) is a hallmark feature of acute heart failure (AHF) and can be measured by evaluating the urinary sodium (UNa) concentration. The aim of this study is to assess the role of measuring IRSA through a random Una-sample and its association with decongestive response.

Methods and results: A post-hoc analysis of the ROSE-AHF trial was performed in all patients with a random UNa spot sample before randomization (n = 339/360). Patients were categorized according to tertiles of UNa as high (range 19-40 mmol/L), intermediate (range 41-68 mmol/L), or low (range 69-139 mmol/L) IRSA. Linear mixed effect models and ANCOVA were used to assess the relation with decongestive effectiveness measured by: (i) weight change, (ii) visual analogue scale (VAS) improvement, (iii) N-terminal pro-B-type natriuretic peptide (NT-proBNP) change, (iv) natriuretic response (UNa in mmol/L), (v) 72 h natriuresis (mmol), (vi) oedema resolution, and (vii) length of stay. High IRSA patients had less improvement in decongestive metrics, including weight loss (p = 0.028), VAS improvement, NT-proBNP decrease, natriuretic response (p-time interaction <0.001 for all), had lower total natriuresis (high IRSA 438 ± 141 mmol, intermediate IRSA 526 ± 320 mmol, and low IRSA 603 ± 276 mmol; p < 0.001), exhibited more oedema at 72 h (p = 0.005), and had a longer length of stay (p = 0.015). Incremental loop diuretic dose titration (± 4 times home dose) after >24 h, resulted in an increase in natriuretic response in the high IRSA group, however cumulative natriuresis still remained lower at 72 h (p < 0.001). Longitudinal UNa profiling of patients with low IRSA showed physiologic breaking in the UNa pattern, associated with attaining decongestion and slight increase in creatinine and cystatin C, forming a potential signal of complete decongestion.

Conclusions: A simple random UNa sample at the time of AHF, gives insight into IRSA which is consistently associated with decongestive effectiveness across multiple metrics, offering an opportunity for early AHF care improvement.

Keywords: Acute heart failure; Care improvement; Decongestion; Natriuresis; Physiology.

© 2022 European Society of Cardiology.

References

    1. Mullens W, Damman K, Harjola VP, Mebazaa A, Brunner-la Rocca HP, Martens P, et al. The use of diuretics in heart failure with congestion - a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2019;21:137-55.
    1. Cotter G, Metzkor E, Kaluski E, Faigenberg Z, Miller R, Simovitz A, et al. Randomised trial of high-dose isosorbide dinitrate plus low-dose furosemide versus high-dose furosemide plus low-dose isosorbide dinitrate in severe pulmonary oedema. Lancet. 1998;351:389-93.
    1. Metra M, Teerlink JR, Cotter G, Davison BA, Felker GM, Filippatos G, et al.; RELAX-AHF-2 Committees Investigators. Effects of serelaxin in patients with acute heart failure. N Engl J Med. 2019;381:716-26.
    1. O'Connor CM, Starling RC, Hernandez AF, Armstrong PW, Dickstein K, Hasselblad V, et al. Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med. 2011;365:32-43.
    1. Packer M, O'Connor C, McMurray JJV, Wittes J, Abraham WT, Anker SD, et al.; TRUE-AHF Investigators. Effect of ularitide on cardiovascular mortality in acute heart failure. N Engl J Med. 2017;376:1956-64.
    1. Felker GM, Lee KL, Bull DA, Redfield MM, Stevenson LW, Goldsmith SR, et al.; NHLBI Heart Failure Clinical Research Network. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med. 2011;364:797-805.
    1. Emmens JE, Ter Maaten JM, Matsue Y, Figarska SM, Sama IE, Cotter G, et al. Worsening renal function in acute heart failure in the context of diuretic response. Eur J Heart Fail. 2022;24:365-74.
    1. Ter Maaten JM, Dunning AM, Valente MA, Damman K, Ezekowitz JA, Califf RM, et al. Diuretic response in acute heart failure - an analysis from ASCEND-HF. Am Heart J. 2015;170:313-21.
    1. Ter Maaten JM, Valente MA, Damman K, Hillege HL, Navis G, Voors AA. Diuretic response in acute heart failure - pathophysiology, evaluation, and therapy. Nat Rev Cardiol. 2015;12:184-92.
    1. Ter Maaten JM, Valente MA, Damman K, Cleland JG, Givertz MM, Metra M, et al. Combining diuretic response and hemoconcentration to predict rehospitalization after admission for acute heart failure. Circ Heart Fail. 2016;9:e002845.
    1. Testani JM, Chen J, McCauley BD, Kimmel SE, Shannon RP. Potential effects of aggressive decongestion during the treatment of decompensated heart failure on renal function and survival. Circulation. 2010;122:265-72.
    1. Testani JM, Kimmel SE, Dries DL, Coca SG. Prognostic importance of early worsening renal function after initiation of angiotensin-converting enzyme inhibitor therapy in patients with cardiac dysfunction. Circ Heart Fail. 2011;4:685-91.
    1. Testani JM, Brisco MA, Chen J, McCauley BD, Parikh CR, Tang WH. Timing of hemoconcentration during treatment of acute decompensated heart failure and subsequent survival: importance of sustained decongestion. J Am Coll Cardiol. 2013;62:516-24.
    1. Testani JM, Brisco MA, Turner JM, Spatz ES, Bellumkonda L, Parikh CR, et al. Loop diuretic efficiency: a metric of diuretic responsiveness with prognostic importance in acute decompensated heart failure. Circ Heart Fail. 2014;7:261-70.
    1. Dauw J, Lelonek M, Zegri-Reiriz I, Paredes-Paucar CP, Zara C, George V, et al. Rationale and design of the Efficacy of a Standardized Diuretic Protocol in Acute Heart Failure study. ESC Heart Fail. 2021;8:4685-92.
    1. Ter Maaten JM, Beldhuis IE, van der Meer P, Krikken JA, Coster JE, Nieuwland W, et al. Natriuresis-guided therapy in acute heart failure: rationale and design of the Pragmatic Urinary Sodium-based treatment algoritHm in Acute Heart Failure (PUSH-AHF) trial. Eur J Heart Fail. 2022;24:385-92.
    1. Martens P, Dupont M, Verbrugge FH, Damman K, Degryse N, Nijst P, et al. Urinary sodium profiling in chronic heart failure to detect development of acute decompensated heart failure. JACC Heart Fail. 2019;7:404-14.
    1. Martens P, Tang WHW, Mullens W. Renal sodium avidity, the prevailing renal target in heart failure. Eur Heart J. 2021;42:4478-81.
    1. Cox ZL, Rao VS, Ivey-Miranda JB, Moreno-Villagomez J, Mahoney D, Ponikowski P, et al. Compensatory post-diuretic renal sodium reabsorption is not a dominant mechanism of diuretic resistance in acute heart failure. Eur Heart J. 2021;42:4468-77.
    1. Chen HH, Anstrom KJ, Givertz MM, Stevenson LW, Semigran MJ, Goldsmith SR, et al.; NHLBI Heart Failure Clinical Research Network. Low-dose dopamine or low-dose nesiritide in acute heart failure with renal dysfunction: the ROSE Acute Heart Failure randomized trial. JAMA. 2013;310:2533-43.
    1. Hodson DZ, Griffin M, Mahoney D, Raghavendra P, Ahmad T, Turner J, et al. Natriuretic response is highly variable and associated with 6-month survival: insights from the ROSE-AHF trial. JACC Heart Fail. 2019;7:383-91.
    1. Testani JM, Hanberg JS, Cheng S, Rao V, Onyebeke C, Laur O, et al. Rapid and highly accurate prediction of poor loop diuretic natriuretic response in patients with heart failure. Circ Heart Fail. 2016;9:e002370.
    1. Martens P, Mullens W. Spot urinary sodium in decompensated heart failure as a prognostic metric for successful ambulatory decongestion. J Card Fail. 2018;24:355-6.
    1. Cunningham JW, Sun JL, Mc Causland FR, Ly S, Anstrom KJ, Lindenfeld J, et al. Lower urine sodium predicts longer length of stay in acute heart failure patients: insights from the ROSE AHF trial. Clin Cardiol. 2020;43:43-9.
    1. Damman K, Beusekamp JC, Boorsma EM, Swart HP, Smilde TDJ, Elvan A, et al. Randomized, double-blind, placebo-controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPA-RESPONSE-AHF). Eur J Heart Fail. 2020;22:713-22.
    1. Mullens W, Verbrugge FH, Nijst P, Martens P, Tartaglia K, Theunissen E, et al. Rationale and design of the ADVOR (Acetazolamide in Decompensated Heart Failure with Volume Overload) trial. Eur J Heart Fail. 2018;20:1591-600.
    1. Trullas JC, Morales-Rull JL, Casado J, Freitas RA, Manzano L, Formiga F. Rationale and design of the "Safety and Efficacy of the Combination of Loop with Thiazide-Type Diuretics in Patients with Decompensated Heart Failure (CLOROTIC) trial:" a double-blind, randomized, placebo-controlled study to determine the effect of combined diuretic therapy (loop diuretics with thiazide-type diuretics) among patients with decompensated heart failure. J Card Fail. 2016;22:529-36.
    1. Mullens W, Dauw J, Martens P, Meekers E, Nijst P, Verbrugge FH, et al. Acetazolamide in Decompensated Heart Failure with Volume Overload trial (ADVOR): baseline characteristics. Eur J Heart Fail. 2022;24:1601-10.
    1. Mullens W, Dauw J, Martens P, et al. Acetazolamide in acute decompensated heart failure with volume overload. N Engl J Med. 2022;387:1185-95.
    1. Ellison DH, Felker GM. Diuretic treatment in heart failure. N Engl J Med. 2017;377:1964-75.
    1. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Bohm M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur J Heart Fail. 2022;24:4-131.
    1. Ahmad T, Jackson K, Rao VS, Tang WHW, Brisco-Bacik MA, Chen HH, et al. Worsening renal function in acute heart failure patients undergoing aggressive diuresis is not associated with tubular injury. Circulation. 2018;137:2016-28.
    1. Mullens W, Damman K, Testani JM, Martens P, Mueller C, Lassus J, et al. Evaluation of kidney function throughout the heart failure trajectory - a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2020;22:584-603.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi